Lubrizol integrates personal, home and health care divisions

16 Jul 2019

The new brand - Lubrizol Life Sciences - aims to maximize client speed-to-market, providing enhanced solutions.

The Lubrizol Corporation has reorganized its personal, home and health care business lines, integrating them under a newly dedicated brand, Lubrizol Life Science.

Lubrizol integrates personal, home and health care divisions

The change reflects the company's commitment to evolve with the beauty, health, home and wellness markets, which continue to cross over and converge. The newly formed Lubrizol Life Science team seeks to enhance the value of its solutions and services to customers and end users through its collective expertise in chemistry, applications and market insights.

"Lubrizol Life Science brings together a great variety of formulation and product development experience to sit under one umbrella," says Lubrizol Advanced Materials President Rick Tolin. "Our internal capabilities are focused and aligned to help our customers quickly meet the expectations of today's consumers for products that ensure them of a healthier, more beautiful and comfortable life."

The newly aligned Lubrizol Life Science team is placing a priority on developing and testing products in partnership with customers, engineering breakthroughs and co-driving initiatives that fuel growth. Practices and processes emphasize agile innovation, enabling the organization to act at the speed of a start-up, while responding with the reach, resources and delivery of a global leader. The new brand will also emphasize the proactive innovation needed to bring market-ready solutions to customers, while capitalizing on the reliability of Lubrizol's 90 years of science and efficacy.

Tolin points out: "Our beauty, health and home customers can count on us bringing truly differentiated products to market, formulated with ingredients that are consumer-driven and backed by the reliability of Lubrizol." Tolin adds, "The Lubrizol Life Science team is poised to service customers throughout the value chain, from concept to commercialization. Once viewed by customers as a chemical and ingredient supplier, we have evolved into an essential, concept-to-commercialization solutions partner."

Lubrizol Life Science also plans to add strategic technology, capability and talent by investing to expand its portfolio, including new acquisitions that bring unique opportunities and synergies.

Read More

Related news

CPhI and AAPS partner to expand expert scientific content at CPhI North America

CPhI and AAPS partner to expand expert scientific content at CPhI North America

10 Jan 2020

CPhI and the American Association of Pharmaceutical Scientists (AAPS) today announced a partnership to expand the scientific content of activities sponsored by CPhI, including CPhI North America—the only event to bring the entire North American pharmac...

Read more 
Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API

Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API

9 Jan 2020

The US arm of generic and specialty pharma company Mylan Pharmaceuticals has recalled three lots of its heartburn drug Nizatidine in capsule form amid fears of possible nitrosamine contamination.

Read more 
New HQ for developer of world's first fully automated drug discovery platform

New HQ for developer of world's first fully automated drug discovery platform

8 Jan 2020

End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.

Read more 
Catalent completes purchase of biologics fill-finish and oral solid dose facility

Catalent completes purchase of biologics fill-finish and oral solid dose facility

7 Jan 2020

Facility provides European customers with great biologics and oral dose capabilities that can help reduce time-to-market.

Read more 
Boxing clever: Smart packs improving communication with patients

Boxing clever: Smart packs improving communication with patients

6 Jan 2020

Drug industry expectations of packaging are evolving with developers now seeking techs that help patients get more from their medicines.

Read more 
WuXi STA opens large-scale oligonucleotide manufacturing facility

WuXi STA opens large-scale oligonucleotide manufacturing facility

6 Jan 2020

Expands company's capacity and capability for this novel modality, providing a one-stop shop from preclinical to commercial.

Read more 
NIH researchers discover new autoinflammatory disease

NIH researchers discover new autoinflammatory disease

3 Jan 2020

Mutations in the RIPK1 gene responsible for CRIA syndrome.

Read more 
UCB to build new biotech manufacturing plant in Belgium

UCB to build new biotech manufacturing plant in Belgium

31 Dec 2019

Capacity to serve global late-stage development and commercial manufacturing of monoclonal antibody drug substance to support new product launches.

Read more 
BioAscent scientists help identify potential new treatments for cancer

BioAscent scientists help identify potential new treatments for cancer

30 Dec 2019

Collaboration discovers potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases.

Read more 
Astellas strengthens immuno-oncology pipeline with acquisition of Xyphos Biosciences

Astellas strengthens immuno-oncology pipeline with acquisition of Xyphos Biosciences

27 Dec 2019

Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy.

Read more